SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77502.12
579.48 (0.75%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
61	Syngene International Ltd.	Q V+ PT	17,420 Small Cap	439.85 (1.92%)	58.23	3.77	10.89	4.48	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
62	Thyrocare Technologies Ltd.	Q V+ PT	8,659 Small Cap	556.85 (2.35%)	54.24	15.31	10.88	8.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
63	Lincoln Pharmaceuticals Ltd.	Q V PT	1,244 Small Cap	625.45 (0.70%)	14.25	1.65	10.63	11.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
64	Indraprastha Medical Corporation Ltd.	Q V+ PT	3,540 Small Cap	389.55 (0.88%)	19.45	4.82	10.30	29.46	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
65	Wanbury Ltd.	Q V+ PT	1,007 Small Cap	286.85 (-0.47%)	15.15	6.94	10.29	30.27	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
66	Zydus Lifesciences Ltd.	Q V PT	1,10,608 Mid Cap	1,099.65 (-0.83%)	21.76	4.22	10.27	30.57	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
67	Artemis Medicare Services Ltd.	Q V PT	4,154 Small Cap	259.15 (-1.24%)	39.66	4.72	10.15	32.48	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
68	Akums Drugs & Pharmaceuticals Ltd.	Q V PT	9,928 Small Cap	637.05 (1.00%)	89.81	4.13	10.00	11.58	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
69	Sun Pharmaceutical Industries Ltd.	Q V+ PT	4,47,704 Large Cap	1,871.55 (0.30%)	39.12	5.37	9.87	23.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
70	Suraksha Diagnostic Ltd.	Q V PT	1,397 Small Cap	271.30 (1.17%)	43.9	5.77	9.86	-51.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
71	Bliss GVS Pharma Ltd.	Q V+ PT	5,566 Small Cap	526.50 (0.31%)	57.64	4.88	9.41	4.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
72	Abbott India Ltd.	Q V PT	54,328 Mid Cap	25,721.65 (0.61%)	35.22	11.45	9.38	18.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
73	Gland Pharma Ltd.	Q V PT	40,632 Small Cap	2,445.50 (-0.72%)	31.04	3.73	9.35	7.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
74	FDC Ltd.	Q V PT	7,007 Small Cap	434.10 (0.86%)	24.72	2.84	9.23	1.32	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
75	Metropolis Healthcare Ltd.	Q V PT	11,232 Small Cap	543.80 (0.38%)	59.34	7.45	9.22	2.10	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
76	Alivus Life Sciences Ltd.	Q V PT	13,922 Small Cap	1,159.50 (2.23%)	25.21	4.27	9.20	6.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
77	Ipca Laboratories Ltd.	Q V+ PT	43,040 Mid Cap	1,718.40 (1.29%)	38.5	5.46	8.87	4.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
78	Kopran Ltd.	Q V PT	912 Small Cap	186.95 (-0.98%)	29.69	2.02	8.61	14.34	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
79	Lupin Ltd.	Q V PT	1,09,576 Mid Cap	2,398.70 (0.09%)	20.57	4.89	8.11	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
80	Cipla Ltd.	Q V PT	1,17,699 Mid Cap	1,456.25 (-0.05%)	30.33	3.42	8.01	10.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
81	Alembic Pharmaceuticals Ltd.	Q V+ PT	16,267 Small Cap	815.20 (-1.49%)	23.75	2.82	7.69	-8.97	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
82	Cohance Lifesciences Ltd.	Q V+ PT	17,265 Small Cap	452.05 (0.17%)	96.49	4.42	7.51	-3.15	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
83	Fermenta Biotech Ltd.	Q V PT	1,043 Small Cap	350.95 (-1.00%)	16.07	2.44	7.46	0.93	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
84	Advanced Enzyme Technologies Ltd.	Q V PT	3,524 Small Cap	313.60 (-0.35%)	26.64	4.95	7.28	11.87	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
85	Shilpa Medicare Ltd.	Q V+ PT	11,165 Small Cap	600.85 (5.26%)	48.29	4.54	7.22	-12.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
86	Laurus Labs Ltd.	Q V+ PT	80,692 Mid Cap	1,525.20 (2.12%)	92.71	15.62	7.19	-2.25	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
87	Hester Biosciences Ltd.	Q V PT	1,866 Small Cap	2,178.65 (-0.67%)	35.57	4.81	6.98	0.80	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
88	Indoco Remedies Ltd.	Q V+ PT	2,186 Small Cap	243.35 (2.74%)	N/A	2.04	6.54	-182.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
89	Dishman Carbogen Amcis Ltd.	Q V+ PT	2,755 Small Cap	188 (7.00%)	30.25	0.44	5.82	-33.01	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
90	Bajaj Healthcare Ltd.	Q V PT	1,162 Small Cap	342.20 (-0.88%)	54.06	2.16	5.76	2.91	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Suven Life Sciences	298.65	8.92%
Themis Medicare	119.15	7.73%
Dishman Carbogen Amc	188	7%
Shilpa Medicare	600.85	5.26%
GPT Healthcare	156.45	4.40%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
KMC Speciality Hosp.	133.60	-5.01%
Morepen Laboratories	59.71	-4.63%
Fischer Medical	39.08	-4.59%
Shree Ganesh Remed.	642.40	-4.38%
Gufic Biosciences	385.40	-2.24%

News about Top Pharma Companies in India

Jul, 2026

Lupin gets EIR from USFDA for Somerset facility

The inspection was conducted from April 13, 2026, to April 17, 2026

Jun, 2026

Shilpa Medicare informs about disclosure

Pursuant to Regulation 30 read with other applicable provisions of the SEBI Listing Regulations, Shilpa Medicare has informed that Shilpa Biologicals (SBPL), a wholly owned subsidiary of the Company, has entered into Co-development and supply agreement with Orion Corporation (‘Orion’) a globally recognized pharmaceutical company headquartered in Finland. Details with respect to the above-mentioned event as required under Regulation 30 of Schedule Ill of the SEBI Listing Regulations and SEBI Circular dated 30th January 2026 are provided in Annexure I to this letter. A press release to be issued in relation to the above matter is enclosed.

The above information is a part of company’s filings submitted to BSE.

Jun, 2026

Bliss GVS Pharma informs about closure of trading window

Bliss GVS Pharma has informed that pursuant to the Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force) and in accordance with the Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons, the Trading window for dealing in securities/shares of the Company will remain closed for Insiders, Designated Persons and their immediate relatives of the Company with effect from Wednesday, July 01, 2026 till completion of 48 hours after the announcement of the Unaudited Financial Results of the Company for the quarter ended on June 30, 2026 generally made available to the public. The Board meeting for the declaration of Unaudited Financial Results for the quarter ended June 30, 2026, shall be intimated later. Accordingly, Insiders, Designated Persons, and their immediate relatives are advised not to trade (buy or sell or pledge, etc.) in the securities/shares of the Company during the aforesaid period of closure of the Trading Window.

The above information is a part of company’s filings submitted to BSE.

Jun, 2026

Alembic Pharmaceuticals gets USFDA’s final approval for Dapsone Gel

Alembic has a cumulative total of 244 ANDA approvals (224 final approvals and 20 tentative approvals) from USFDA

Jun, 2026

FDC informs about disclosures

FDC has informed that the Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mohan Anand Chandavarkar Trust (through its Managing Trustee Nandan Mohan Chandavarkar) & PACs.

The above information is a part of company's filings submitted to BSE.

Jun, 2026

Alembic Pharma rises on getting USFDA’s approval for Oseltamivir Phosphate for Oral Suspension

Alembic has a cumulative total of 243 ANDA approvals (223 final approvals and 20 tentative approvals) from USFDA

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Health X Platform Ltd.	1,009 Crore
2	Fischer Medical Ventures Ltd.	2,681 Crore
3	3B Blackbio Dx Ltd.	1,028 Crore
4	Max Healthcare Institute Ltd.	1,10,950 Crore
5	Indegene Ltd.	12,364 Crore
6	Acutaas Chemicals Ltd.	29,259 Crore
7	Rubicon Research Ltd.	22,613 Crore
8	Yatharth Hospital & Trauma Care Services Ltd.	8,257 Crore
9	Dr. Agarwals Health Care Ltd.	14,873 Crore
10	Innova Captab Ltd.	5,575 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	25,722	54,328	35.00	11.38	23.88	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,663	1,57,093	72.61	18.73	38.24	29.04
Ajanta Pharma Ltd. (M)	Very Good	3,344	41,813	39.60	9.24	26.75	25.35
Lupin Ltd. (M)	Somewhat Good	2,399	1,09,576	20.55	4.88	11.89	20.83
Zydus Lifesciences Ltd. (M)	Very Good	1,100	1,10,608	21.95	4.25	13.46	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,525	80,692	101
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,318	36,871	41.28
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,663	1,57,093	39.25
Aurobindo Pharma Ltd. (M)	Very Good	1,560	89,345	34.75
Ajanta Pharma Ltd. (M)	Very Good	3,344	41,813	31.18
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,318	36,871	54.70	9.13	33.13	15.51
Mankind Pharma Ltd. (M)	Very Good	2,487	1,02,844	50.47	6.27	31.70	14.65
Ajanta Pharma Ltd. (M)	Very Good	3,344	41,813	39.60	9.24	26.75	13.54
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,346	1,11,792	26.64	2.95	14.87	13.26
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,663	1,57,093	72.61	18.73	38.24	11.80

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	1,100	1,10,608	21.95	4.25	13.46	30.57
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,872	4,47,704	39.00	5.36	22.34	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,346	1,11,792	26.64	2.95	14.87	22.29
Abbott India Ltd. (M)	Very Good	25,722	54,328	35.00	11.38	23.88	18.78
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,195	60,890	44.71	5.79	11.86	14.41

You have 9 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Lupin gets EIR from USFDA for Somerset facility

Shilpa Medicare informs about disclosure

Bliss GVS Pharma informs about closure of trading window

Alembic Pharmaceuticals gets USFDA’s final approval for Dapsone Gel

FDC informs about disclosures

Alembic Pharma rises on getting USFDA’s approval for Oseltamivir Phosphate for Oral Suspension

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.